Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
77.23(c) 76.61(c) 76.75(c) 76.19(c) 75.58(c) Last
14 233 205 19 351 902 10 880 842 10 957 476 9 516 720 Volume
+0.81% -0.80% +0.18% -0.73% -0.80% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 48 016 M - -
Net income 2021 12 084 M - -
Net Debt 2021 11 622 M - -
P/E ratio 2021 15,6x
Yield 2021 3,44%
Sales 2022 50 139 M - -
Net income 2022 13 724 M - -
Net Debt 2022 5 995 M - -
P/E ratio 2022 13,5x
Yield 2022 3,71%
Capitalization 191 B 191 B -
EV / Sales 2021 4,23x
EV / Sales 2022 3,94x
Nbr of Employees 73 500
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
06/22 | 09:00amInvestor Meeting
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
04:15pRUBIUS THERAPEUTICSá : First Patient Dosed in Rubius Therapeutics' Trial For Adv..
MT
10:17aMERCKá : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overa..
AQ
04:52aBAYERá : Merck & Co Heart Failure Drug Verquvo Wins Japanese Approval
MT
06/22MERCKá : Says Phase 3 Trial Met Endpoints of Overall Survival, Progression-Free ..
MT
06/22MERCKá : Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overa..
BU
06/22Merck's Keytruda Meets Main Endpoints in Cervical-Cancer Study
DJ
06/22ASTRAZENECAá : Gets European Commission's Conditional Approval for Koselugo in P..
MT
06/22ASTRAZENECAá : Merck & Co. Win Conditional EU Nod for Rare Disease Drug in Child..
MT
06/21MERCKá : CONSOLIDATED STATEMENT OF INCOME - GAAP (Form 8-K)
PU
06/21MERCK & CO., INC.á : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
06/17MERCKá : Unveils Supply Deal With US Government for Investigational Therapy Moln..
MT
06/17MERCKá : to Participate in the Guggenheim Biopharma Strategy Series
BU
06/16MERCKá : Announces the Kenneth C. Frazier Award for Maternal Health Equity to Ac..
BU
06/14MERCK & CO., INC. : Ex-dividend day for
FA
06/09MERCKá : to Supply COVID-19 Drug Molnupiravir to US for $1.2 Billion
MT
More news
News in other languages on MERCK & CO., INC.
04:06aBayer-Herzmedikament Verquvo in Japan zugelassen
06/22MERCKá : nouvel essai prometteur pour Keytruda
06/22Keytruda von Merck & Co auch gegen Gebärmutterhalskrebs wirksam
06/19LEVOTHYROX : nouveau sursis pour l'ancienne formule, disponible jusqu'à fin 2022
06/17USA investieren 3,2 Milliarden Dollar in Entwicklung antiviraler Medikamente
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 75,58 $
Average target price 95,45 $
Spread / Average Target 26,3%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-6.86%192 918
JOHNSON & JOHNSON3.96%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.7.61%221 725
NOVARTIS AG2.56%209 282
ABBVIE INC.7.05%202 586